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Objectives: Altered awareness of cognitive and neuropsychiatric symptoms is a com-
mon feature of neurodegeneration, which can significantly impact on quality of life,
medication concordance and personal safety. Elucidating how awareness is affected
by common alpha-synucleinopathies therefore has significant clinical relevance. We
performed a systematic review of the literature on awareness of cognitive and neuro-
psychiatric symptoms in Parkinson's disease and Dementia with Lewy Bodies.
Methods: Searches of PubMed and Web of Science were carried out, using keywords
and MeSH subheadings, limited to papers in English dealing with humans. The terms
“Parkinson's” or “Lewy body” were used to denote the disease of interest, combined
with either “agnosia”, “anosognosia”, “insight”, “metacognition”, or “neuropsychology”
to denote the neuropsychological area of interest.
Results: 21 publications investigating awareness of cognitive symptoms, and 18 publi-
cations on awareness of neuropsychiatric symptoms were identified. The large major-
ity focused on Parkinson's disease rather than Dementia with Lewy Bodies.
Cognitively intact people with Parkinson's disease may over-report cognitive symp-
toms, whilst those with cognitive impairment under-report symptoms. Awareness of
neuropsychiatric symptoms is likely to decline over time, particularly in those with
progressive cognitive impairment.
Conclusions: Altered awareness of cognitive and neuropsychiatric symptoms is com-
mon in Parkinson's disease. Symptom awareness varies significantly between individ-
uals, and appears to be influenced by mood and global cognitive functioning, with
executive functioning specifically implicated. There are gaps in our understanding of
how dopaminergic medications influence symptom awareness, and a need for longi-
tudinal studies of how awareness changes over time in Parkinson's disease and
Dementia with Lewy Bodies.
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1 | INTRODUCTION
Cognitive and neuropsychiatric symptoms are common manifestations
of Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB).1,2
Altered awareness of cognitive and neuropsychiatric symptoms can
have a significant impact not only on quality of life for the affected
individual, but also their significant others or carers.3 Those affected
are frequently not fully consciously aware of their symptoms. Patients
may decline therapies, become distressed by hallucinations or delu-
sions, or be driven to potentially dangerous actions such as searching
for the source of a hallucination. They may continue to carry out high
risk activities, such as driving or making financial transactions, despite
being cognitively compromised.
Cognitive decline is a common consequence of PD, with mild cog-
nitive impairment being already present in around 30% of patients at
the time of their PD diagnosis. Parkinson's Disease with Mild Cogni-
tive Impairment (PD-MCI) confers an increased risk of future PD
dementia.4,5 Longitudinal studies indicate that the majority of people
with PD will ultimately develop dementia.1 Typically a profile of exec-
utive dysfunction, attentional deficits and visuospatial difficulties is
seen, with memory being affected to a lesser extent.6 This is a close
match to the profile seen in DLB.2 Clinically and pathologically,
Parkinson's disease dementia (PDD) is closely related to DLB, and the
two conditions are viewed as part of the alpha synucleinopathy spec-
trum, with a clinical distinction being drawn according to the temporal
order of onset of motor or cognitive symptoms.2,7
Neuropsychiatric manifestations of PD and DLB include depres-
sion, anxiety, apathy, psychotic symptoms, impulse control disorders
and sleep disorders.2,8 Strong associations are seen between neuro-
psychiatric symptoms and cognitive decline in PD, with higher preva-
lence in those with MCI or dementia.8 Depression has been reported
in over half of cognitively intact people with PD, and 70% of those
with amnestic MCI.9 Anxiety and apathy is also common, and apathy
is reported in up to 50% of people with PDD.10 Visual hallucinations
are a key feature of DLB, and form part of the diagnostic criteria.2
They are typically formed and feature animals or people. In PD, a
range of psychotic experiences may occur.11,12 PD psychosis is
recognised to encompass a spectrum of symptoms, often with a pat-
tern of increasing severity and complexity as PD progresses. Early fea-
tures include the feeling of another being present (presence
hallucinations) and passage hallucinations - the experience of some-
one or something moving across the edge of the visual field. Visual
illusions and formed hallucinations may also occur, with preserved
insight early on. Later in the disease course, insight is lost and other
sensory modalities can be involved, with auditory, tactile and olfactory
hallucinations reported. Delusions can arise, often with paranoid idea-
tion, and rarely misidentification syndromes such as Capgras delusion.
Loss of symptom awareness is a prominent feature of many forms
of neurodegeneration, and has been most widely studied in
Alzheimer's disease (AD), where it increases in proportion to the
severity of cognitive impairment.13 How awareness is affected by
common alpha-synucleinopathies is less well understood. We now
recognise that cognitive impairment is very common in PD, with
around 80% of people developing dementia at some point in the dis-
ease process.14 A diagnosis of PD-MCI or PDD can utilise reports from
patients, caregivers and clinicians. Knowing how reliable patient reports
are, and understanding how cognitive symptom awareness may interact
with cognitive impairment in PD, is crucial in order to make an accurate
clinical assessment. Inaccurate symptom reporting may also affect med-
ical management decisions and clinical trial outcomes. Just as there are
multiple cognitive domains, we can regard symptom awareness as seg-
regating across different domains - with awareness of memory func-
tioning being distinct from awareness of visuospatial functioning, for
example.15,16 Impaired executive functioning is often postulated as a
cause of reduced symptom awareness.13 One of the aims of this review
is to examine how symptom awareness interacts with different cogni-
tive domains, both in terms of accuracy of self-knowledge, and links
between cognitive impairment and the severity of altered awareness.
Neuropsychiatric symptoms may also be affected by loss of aware-
ness, and this is acknowledged in the current PD psychosis defini-
tions.11 Neuropsychiatric symptoms may only become obvious when
the affected individual actively reports them - hallucinations will only
be evident if the person describes them, or is observed to interact with
them. Similarly mild depression, anxiety or apathy may be purely inter-
nal experiences for the patient, and not obvious to external observers.
Therefore the accuracy of self-report becomes critical for evaluation,
treatment and research into neuropsychiatric symptomatology.
The aims of this review are to synthesise the literature investigating
awareness of cognitive and neuropsychiatric symptoms in PD and DLB.
We will review the existing knowledge base of how symptom awareness
varies across different cognitive domains and neuropsychiatric symptom
types. We will discuss how global and domain specific cognitive function-
ing interacts with symptom awareness, and the potential impact of dopa-
minergic therapies. We will evaluate the methodologies used in the field
of symptom awareness, and highlight gaps in our understanding of symp-
tom awareness in common alpha synucleinopathies.
2 | METHODS
A systemic review was undertaken of the literature investigating
altered symptom awareness in PD and DLB across motor symptoms,
Key points
• Altered awareness of cognitive and neuropsychiatric
symptoms is common in Parkinson's disease.
• Awareness of neuropsychiatric symptoms appears to
decline over time in people with Parkinson's disease, partic-
ularly in those with cognitive impairment.
• Cognitively intact people with Parkinson's disease may
over-report cognitive symptoms.
• There is a lack of research on symptom awareness in peo-
ple with Dementia with Lewy Bodies.
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TABLE 1 Studies of awareness of cognitive symptoms in PD and DLB
Study Study groups Age (Yearsa)
Disease duration
(Monthsa)
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cognitive and neuropsychiatric symptoms. The findings for awareness
of cognitive and neuropsychiatric symptoms are reported in the cur-
rent publication. In order to capture the extent of the literature a
range of search terms were used. Either “Parkinson's” or “Lewy body”
were used as a term to denote the disease of interest, combined with
either “insight”, “anosognosia” or “metacognition” to denote the neu-
ropsychological area of interest. PubMed and Web of Science
searches were conducted between January and March 2019. An addi-
tional MeSH term search was carried out in June 2020, using search
terms of “Parkinson's disease” or “Lewy body” to denote the disease
of interest, combined with either “metacognition” or “agnosia” or
“awareness” or “neuropsychology”. Studies published in English and
including human participants with PD (of any cognitive status) and/or
DLB, and reporting a measure of symptom awareness were deemed
eligible. Duplicates were excluded. 1747 publications were identified,
with 366 retained after title screening, and 97 after abstract screen-
ing. 26 relevant publications detailing investigations of symptom
awareness in people with PD or DLB were then selected after a full
review of the text. An additional 28 studies were identified by manual
screening of references from the selected publications. A PRISMA
systematic review flow diagram17 and a PRISMA checklist are avail-
able in supplemental data.
Conference abstracts were included if these were indexed for
MEDLINE and included essential study data such as group sizes and
results data. Data was then extracted following a standardised format,
capturing group sizes and diagnosis, baseline group age and cognitive
functioning, the nature of the measure of symptom awareness, and
study findings. The medication status during assessment was
dichotomised to being ON medication, referring to participants being
within the therapeutic window of their dopaminergic medication, or
OFF medication, referring to participants being out with the therapeu-
tic phase of their dopaminergic medication.
3 | RESULTS
3.1 | Literature search
A total of 1747 publications were identified from the search. 366
were retained following title screening, 97 after abstract screening
and 26 after full text review. A further 28 relevant publications were
identified from references in screened literature. These were then
sub-divided according to whether their primary objective was investi-
gation of awareness of cognitive symptoms (Table 1; 21 publications),
neuropsychiatric symptoms (Table 4; 18 publications), or motor symp-
toms (reported elsewhere18; 15 publications). Key findings of studies
of awareness of cognitive symptoms are shown in Table 2, and of
awareness of neuropsychiatric symptoms in Table 5.
3.2 | Participant groups
Most studies of cognitive symptom awareness actively excluded par-
ticipants with dementia, and no studies including participants with
DLB were found (Table 1). Only 1 study recruited people with PDD,
whilst 4 included a specific PD-MCI group. Review of the mean global
cognitive scores of studies of cognitive symptom awareness shows
that many are likely to have included individuals with PD-MCI or mild
PDD. Basic et al.19 reported a mean Mini-Mental State Examination
(MMSE) of 26.1 (SD 2.76) in their PD group, and acknowledged that
TABLE 1 (Continued)
Study Study groups Age (Yearsa)
Disease duration
(Monthsa)
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18 AD
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Abbreviations: ICD, Impulse Control Disorder.
aAge and disease duration are given as mean values unless otherwise stated. The recruitment avenue for patients (not healthy controls) is shown.
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some participants likely had mild dementia. Oh-Lee et al.20 recruited a
PD group with a mean MMSE of 25.36 (SD 2.80), a value which sug-
gests the group may include people with PD-MCI and PDD.
Definitions of PD-MCI varied; Baran et al.21 recruited subjects
with performance in 2 cognitive domains 1.5 standard deviations
below age and education predicted norms, Cambridge Dementia
TABLE 2 Awareness of cognitive symptoms: key findings
Study Key findings
Baran et al.21 FoK judgements at chance level in PD-MCI group, with evidence of over-confidence.
FoK linked to executive functioning in controls but not in people with PD-MCI.
Basic et al.19 PD group self-rated their memory for new information as more impaired than their carers did, suggesting that subtle memory
issues may not be noticed by carers.
Castro et al.50 Subjects who self-reported cognitive problems had intact cognition but more depressive & neuropsychiatric symptoms. Those
without subjective problems had objective cognitive impairment, suggesting altered awareness in both groups.
Ivory et al.47 PD subjects had intact memory awareness & FoK judgements, despite mild memory impairments.
Johnson et al.48 Those with PD self-reported intact meta-memory but made less use of strategies to aid memory (especially external strategies for
example, diaries, environmental cues).




People with PD & executive dysfunction showed impaired performance monitoring, with over confidence. People with PD &
intact executive function rated themselves as being more impaired than informants did.
Lehrner et al.52 Those with amnestic MCI (with or without PD) had worse awareness of cognitive functioning than controls, but not as severe as
AD subjects. Over-estimation of memory function correlated with reduced cognition (particularly memory), increasing age, and
lower levels of depression.
Mack et al.27 Those with ICD reported more executive dysfunction, despite performing at same level as those without ICD.
Those with ICD showed greater insight & a trend towards greater self-reflectiveness.
Marino et al.58 Measures of perceived cognition from the PDQ-39 moderately associated with Geriatric Depression Scale (GDS) scores. No
correlations between performance on tests of memory or frontal lobe function and GDS scores or self-perceived cognition
ratings on the PDQ-39. MMSE scores correlated with the perceived cognition item of PDQ-39, but not with scores on the
Mattis DRS. Self-perceived cognition appears to be more influenced by mood than cognitive ability.
McNamara
et al.60
People with PD showed impaired monitoring of speech errors compared to healthy controls, although this was not as severe as in
AD subjects. Naming ability negatively correlated with the number of uncorrected errors.
Oh-Lee et al.20 “Tip of the tongue” metamemory ability was not impaired in those with PD.
Orfei et al.22 Loss of awareness for cognitive impairment was associated with lower depressive symptoms in cognitively intact PD & multi-
domain PD-MCI.
A diagnosis of anosognosia on the Anosognosia Questionnaire-Dementia was made in 36% of PDD and 16% of the multi-domain
PD-MCI group.
Seltzer59 PD group unaware of social and self-care symptoms, but retained insight into cognition.
Level of unawareness in PD patients correlated with cognitive functioning.
Sitek et al.55 No discrepancy between patient & carer rating of overall memory functioning.
Patient & carer ratings of overall memory functioning moderately consistent with objective memory performance.
Patients over-estimated memory dysfunction on individual memory items; associated with poorer objective memory function and
cognitive control, greater PD severity & depression.
Sitek et al.57 Those with mild PD rated their executive function as better than their informants did, whereas the converse was true for people
with advanced PD. People with advanced PD underperformed on a test of executive function, whereas those with mild PD
performed normally.
Smith et al.54 People with PD were inaccurate when predicting how they would perform on a prospective memory task, but accurate at rating
their performance after the task. This suggests impaired knowledge of memory ability, but intact monitoring ability.
Souchay et al.53 Both people with PD & controls slightly under-estimated episodic memory ability. People with PD had reduced FoK accuracy. This
suggests that memory knowledge is intact in PD but monitoring of memory performance is impaired.
Trenado et al.42 On a reversal learning task, accuracy and confidence correlated in controls and people with PD when OFF medication. When OFF
medication participants had reduced memory awareness.
Yu et al.49 FoK on an episodic memory task reduced in people with akinetic/rigid PD, but intact in those with tremor predominant PD. FoK
related to memory performance in the akinetic/ rigid group, and executive function in the tremor predominant group.
Zec et al.24 AD participants self-rated themselves as being less impaired than control, but were actually more impaired. PD group tended to
rate themselves as more impaired than independent raters did.
Abbreviations: FoK, Feeling of Known; Mattis DRS, Marris Dementia Rating Scale, PDQ-39, Parkinson's Disease Questionnaire-39.
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TABLE 3 Awareness of cognitive symptoms: study quality summary
Study Measure of awareness Study quality summary
Baran et al.21 Feeling of Knowing judgements Case-control study. Small group sizes, well
characterised. Participants excluded if
MMSE<24. Medication status during
assessment not stated.
Basic et al.19 Brief questions about subjective changes to
cognition
Case-control study. Good group sizes.
Limited, subjective assessment of
awareness. Medication status during
assessment not stated.
Castro et al.50 Self-report of cognitive symptomatology Case-control study. Small group sizes, well
characterised.
Medication status during assessment not
stated.
Ivory et al.47 Feeling of Knowing judgements Case-control study. Small group sizes; PD
severity not reported.
PD participants assessed ON medication.
Johnson et al.48 Metamemory In Adulthood questionnaire
(self-report)
Case-control study. Good group sizes but
limited characterisation.
Medication status during assessment not
reported.
Koerts et al.56 Discrepancy scores: subject vs informant
ratings on the Dysexecutive
questionnaire
Case-control study. Good group sizes; well
characterised; excluded if MMSE<24.
PD participants assessed ON medication.
Kudlicka & Hindle51 Discrepancy scores: subject vs informant
ratings on the BRIEF-A executive
function questionnaire
Case-control study. Good group sizes, well
characterised, excluded if MMSE<24.
PD participants assessed when ON
medication.
Lehrner et al.52 Memory self-rating vs objective
performance on the Neuropsychological
Test Battery Vienna
Case-control study. Good group sizes; PD
severity not stated.
Medication status of PD subjects during
assessment not stated.
Mack et al.27 Discrepancy scores: subject vs informant
ratings on DEX & Everyday Memory
Questionnaire-Revised
Case-control study; small group sizes. Well
characterised; excluded if MMSE<24.
PD participants assessed whilst ON
medication.
Marino et al.58 Comparison of self-rated cognition on
PDQ-39 items and GDS score with
performance on: MMSE, Mattis DRS,
COWA, Animal naming, Stroop, TMT &
HVLT.
Cross-sectional study with no control
group. Cognitive status & recruitment
source not stated. Medication status and
PD severity not stated. Those with
clinical depression excluded.
McNamara et al.60 Boston Cookie Theft task with
measurement of corrected & uncorrected
speech errors.
Case-control study; small group sizes.
Limited characterisation; those with
dementia excluded. Medication status
during assessment not stated.
Oh-Lee et al.20 Tip of the Tongue metamemory task &
motor timing task.
Case-control study; small group sizes;
limited group characterisation.
PD subjects assessed ON medication.
Orfei et al.22 Discrepancy scores: subject vs informant
ratings on the Anosognosia
Questionniare - dementia
Case-control study; good group sizes, well
characterised.
Medication status of PD subjects during
assessment not stated.
Seltzer59 Discrepancy scores: subject vs informant
ratings on Patient Competency Rating
Scale
Case-control study; medium group sizes;
well characterised groups.
Medication status of PD subjects during
assessment not stated.
Sitek et al.55 Discrepancy scores: subject vs informant
ratings on Self-Rating Scale of Memory
Functions
Cross-sectional study; medium group size;
well characterised. Those with MMSE<23
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Rating Scale (CDR) of 0.5 and MMSE of 24 or greater; Orfei et al.22
applied the Movement Disorder Society criteria for PD-MCI and PDD.
Martínez-Martín et al.23 used the Unified Parkinson's Disease Rating
Scale (UPDRS), Pfeiffer's Short Portable Mental Status Questionnaire,
and neurologist and care-giver ratings, whilst Zec et al.24 reported
PD-MCI subjects as having an MMSE of > = 26, without providing fur-
ther details of their definition of PD-MCI.
Studies of neuropsychiatric symptoms included participants with
PDD (2 studies), DLB (2 studies), cognitively intact people with PD
(7 studies) and groups containing people with PD with varied levels of
cognitive functioning (8 studies). The mean MMSE (or similar global
cognitive measure) is shown in Table 4. Various global cognitive mea-
sures were used; the MMSE (9 studies1,25-32), the Mattis Dementia
Rating Scale (Mattis-DRS; 2 studies33,34), and in one study each the:
CDR,35 mini-mental Parkinson's,36 National Adult Reading Test IQ
(NART IQ),37 Telephone Interview for Cognitive Status (TICS),38 Func-
tional Dementia Scale (FDS),39 Dementia Rating Scale-2 (DRS-2).40
1 study described 15% of participants as having dementia, but did not
give further details.41
Study group sizes were highly variable: in the cognitive studies:
the smallest group numbered 10 participants42 and the largest 197,22
whilst in neuropsychiatric studies this ranged from 1535 to 25043
participants.
3.3 | Techniques for assessing symptom
awareness
Various methods were used to quantify symptom awareness (Tables 3
and 6). Techniques used to evaluate awareness of cognitive function-
ing included discrepancy scores between self and informant or clini-
cian ratings, comparison of self-ratings and objective performance on
cognitive tasks, Feeling of Knowing tasks or Judgement of Learning
tasks, and self-report questionnaires. When evaluating insight into
neuropsychiatric symptoms, direct self-report was often used (ie,
directly enquiring if the person thought their hallucinations were real
or not; 9 out 18 studies), followed by discrepancy scores (where the
participant is asked to rate their own ability, symptom or performance,
and this score compared to that given by a knowledgeable informant
or expert rater; 8 studies) on a variety of questionnaires evaluating
different neuropsychiatric symptoms. 1 study relied on informant
reports.
TABLE 3 (Continued)
Study Measure of awareness Study quality summary
excluded. Medication status of PD
subjects during assessment not stated.
Sitek et al.57 Discrepancy scores: subject vs informants
on Dysexecutive function questionnaire
Case-control study; small group sizes; well
characterised.
Medication status of PD subjects during
assessment not stated.
Smith et al.54 Prospective time or event-based memory
tasks & self-ratings of prospective &
retrospective memory.
Case-control study; small group sizes; well
characterised.
Medication status of PD subjects during
assessment not stated.
Souchay et al.53 Prediction of performance on a word pair
association task, & Feeling of Knowing
judgements.
Case-control study; small groups; limited
characterisation; excluded if MMSE<24.
PD participants assessed ON medication
Trenado et al.42 Reversal learning task with confidence
ratings after each trial.
Case-control study; small groups; well
characterised; excluded if Mattis
Dementia Rating score < =132 or Beck
Depression Inventory > = 18. PD
participants assessed ON and OFF
medication.
Yu et al.49 Feeling of Knowing episodic memory task. Case-control study; well characterised;
small group sizes; excluded if MMSE<24.
Medication status of PD participants during
assessment not stated.
Zec et al.24 Discrepancy scores: subject vs informant on
Dysexecutive Self-Rating & Dysexecutive
Independent Rating
Case control study; small group sizes; PD
subjects & controls excluded if
MMSE<26.
Medication status of PD participants during
assessment not stated.
Abbreviations: BRIEF-A, Behaviour Rating Inventory of Executive Function, Adult version; COWA, Controlled Oral Word Association Test; DEX,
Dysexecutive Questionnaire; HVLT, Hopkins Verbal Learning Test; TMT, Trail Making Task.
PENNINGTON ET AL. 7
TABLE 4 Studies of altered awareness of neuropsychiatric symptoms in PD and DLB
Study Study participants Age (Yearsa)
Disease duration
(Monthsa)




Aarsland et al.65 235 people with PD 73.6 109.2 24.5 Community &
Specialist
clinics




Not stated DLB group: 14.9
AD group: 13.9
Specialist clinics
Fenelon et al.36 52 PD with feeling of
presence
67.0 138.0 Mean Mini Mental Parkinson's
cognitive








69.0 144.0 15% had dementia at baseline (no




89 PD 67.7 123.6 26.9 Specialist clinics
















PD no hallucinations: 111.7
PD with hallucinations: 108.6
Specialist clinics
Holroyd et al.38 98 PD 67.5 116.4 Mean TICS (normal range 31 to
41)
PD with hallucinations: 29.9
PD without hallucinations: 33.0
Specialist clinics
Llebaria et al.33 28 PD no
hallucinations




























Major hallucinations with insight:
121.2
Major hallucinations, no insight:
110.2
Specialist clinics
Mack et al.43 250 PD 66.3 93.6 28.3 Specialist clinics
Mathias39 30 PD
30 controls
63.7 64.8 FDS mean score 24.5 (little or no





McKinlay et al.28 43 PD 66.5 72.0 28.5 Community

















77% of participants CDR 1
17% of participants CDR 2





70 PD 64.3 110.4 25.6 Specialist clinics
Serrano &
Serrano30
70 PD 70.5 90.0 26.7 Specialist clinics




PD: 80.88 No evidence of dementia &
Mattis DRS score > =130
Specialist clinics




Not stated PDD group: 20.3
AD group: 20.3
Specialist clinics
Valentino et al.32 48 PD 72.21 72.24 22.83 Specialist clinic
aAge and disease duration are given as mean values unless otherwise stated.
8 PENNINGTON ET AL.
TABLE 5 Awareness of neuropsychiatric symptoms: key findings
Study Key findings
Aarsland et al.65 9.8% had hallucinations with insight; 6.0% had hallucinations/delusions without insight.
Loss of insight was associated with cognitive decline, PD severity, and depression.
Altered insight best explained by MMSE score.
Ballard et al.25 Hallucinations were commoner in DLB (93% of subjects vs 27% of those with AD).
63% of people with DLB and hallucinations had no insight into these.
No correlations between MMSE, dopaminergic or anticholinergic medication use and hallucinations.
Fenelon et al.36 77% of those reporting feeling of presence retained insight, whilst insight was lost in 23%. Those without insight had
significantly higher mean BDI-II scores (19.8 vs 25.4) & lower MMP (26.2 vs 22.8).
Goetz et al. 200641 81% of those with PD and hallucinations lost insight over a median of 2 years.
The presence of dementia at baseline did not increase the likelihood of conversion to hallucinations without insight.
Most of those who retained insight had a reduction in PD medication prescription.
Goetz et al. 201026 22.5% had hallucinations with insight at baseline, whilst 10.1% had hallucinations without insight. Baseline PSQI score did not
correlate with MMSE or UPDRS motor score. Higher severity scores on the Rush Hallucination Inventory were associated
with lower MMSE scores and higher UPDRS motor scores at baseline. Hallucination prevalence and severity increased over
time. Only 4 subjects were hallucination free at final 10 year follow up.
Graham et al.37 70.4% of those with hallucinations retained insight. Other data not broken down by insight status.
Holroyd et al.38 26.5% of the group had visual hallucinations (N = 26). Of those with hallucinations, 46.2% had full insight, 38.5% had partial or
variable insight, and 15.4% had no insight. Cognitive scores did not vary between these sub-groups.
Llebaria et al.33 No cognitive differences emerged between those without hallucinations & those with minor hallucinations.
Action verbal fluency was significantly worse in those with major hallucinations (with insight) & those with minor
hallucinations.
Posterior cortical score & clock copying were significantly worse in those with major hallucinations without insight than people
with major hallucinations & retained insight.
Mack et al.43 20.4% of subjects with PD had hallucinations or illusions with insight
5.6% had hallucinations or illusions with no insight.
Mathias39 Good agreement on reporting of neuropsychiatric symptoms between people with PD and informants.
The only significant discrepancy was on reporting of depressive symptoms.
No evidence of loss of awareness.
McKinlay et al.28 Low level of agreement between subjects with PD and informants: 45.8% for depression, 45% for apathy, 28.6% on
hallucinations, 26.9% on sleep issues, 6.7% for anxiety.
Most hallucinations were not reported by carers.
Mikos et al.40 No group difference in self & informant ratings, but variable discrepancies in individuals.
Higher levels of apathy in those with PD who under-reported reduced expressivity.
Noe et al.35 Psychosis (delusions or hallucinations) were commoner in DLB (31.3%) than PDD.
Papapetropoulos
et al.29
31 participants had hallucinations. 35.5% retained insight, 25.5% had intermittent insight (sometimes thinking hallucinations
were real), 32.3% did not have any insight, and 9.7% were unsure if hallucinations were real or not. There was no difference
in MMSE scores between those with different levels of insight.
Serrano &
Serrano30
Low correlation between ratings by people with PD and their informants on the Neuropsychiatric Inventory: Questionnaire.
Schiehser et al.34 Moderate agreement was seen on the Frontal Systems Behavior Scale (FrSBe) for prediagnosis ratings of apathy and executive
dysfunction (ICC between 0.4 and 0.59) but poor agreement on disinhibition prediagnosis (ICC <0.4). Patients reported
greater symptoms prediagnosis than informants did.
Higher Ldopa usage was associated with greater discrepancy on apathy scores, for both prediagnosis and current apathy. No
other associations found between patient factors (mood, cognition, motor symptoms, Ldopa usage) & discrepancy scores for
disinhibition, executive function or apathy. Higher Ldopa usage associated with higher apathy ratings.
Higher levels of medication usage associated with carer ratings of executive dysfunction.
Higher carer burden & depression levels were significantly associated with greater discrepancies in prediagnosis & current
apathy ratings. Higher levels of carer burden associated with greater discrepancy in prediagnosis & current disinhibition
ratings. No associations between care burden or depression and executive function ratings.
Starkstein et al.31 More severe anosognosia & disinhibition in AD compared to PDD.
Higher prevalence of major depression & worse visual reasoning in PDD.
Valentino et al.32 Patients' self-rated apathy scores were higher than carer ratings - both for the total AES score & the emotional apathy sub-
score. No differences were found between self & carer ratings on the cognitive & behavioural apathy sub-scores.
Self & carer apathy ratings positively correlated with severity scores on the UPDRS-3, H&Y & NPI-P. An inverse correlation
was found between self-rated apathy scores & MMSE & FAB scores (but no correlations emerged with carer scores). Neither
self-ratings or carer ratings correlated with HDRS scores.
Abbreviations: AES, Apathy Evaluation Scale; FAB, Frontal Assessment Battery; HDRS, Hamilton Depression Rating Scale; H&Y, Hoehn and Yahr scale;
NPI-P, Neuropsychiatric Inventory - patient version; PSQI, Pittsburgh Sleep Quality Index.
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TABLE 6 Awareness of neuropsychiatric symptoms: study quality summary
Study Mesure of awareness Study quality summary
Aarsland et al.65 Self-reports on the UPDRS Thought
Disorder scale
Cross-sectional study. No comparator
group. Large, well characterised
population; MMSE reported. Medication
status at time of assessment not stated.
Ballard et al.25 Discrepancy scores: subject vs informant on
a study specific questionnaire
Case control study: DLB and AD groups.
Well characterised groups. MMSE
reported.
Medication status at time of assessment not
stated.
Fenelon et al.36 Structured questionnaire for feeling of
presence & insight. BDI-II & MMP.
Cross-sectional study. Good group sizes,
well characterised. Insight only report in
terms of BDI-II scores & not analysed in
reference to other variables.
Goetz et al.41 Self-reports on the UPDRS Thought
Disorder scale
3 year longitudinal study. No comparator
group. Cognitive evaluation performed,
but only presence or absence of
dementia reported. Medication status at
time of assessment not stated.
Goetz et al. 201026 UPDRS modified thought disorder stratum 10 year longitudinal study. No comparator
group. Good group size. MMSE reported,
Medication status at time of assessment
not stated.
Graham et al.37 Psychosis questionnaire (self-report),
UPDRS, neuropsychological assessment.
Longitudinal study but only very limited
baseline data on insight presented. Good
group size, well characterised. Motor
assessments carried out ON medication.
Medication status during other
assessments not stated.
Holroyd et al.38 Self-report of hallucinations & insight into
these. TICS, UPDRS, GDS.
Cross-sectional study. Moderate group size,
well characterised but only limited data
reported specifically in relation to insight.
Those with delirium or non-PD related
psychosis excluded. Medication status
during assessment not stated.
Llebaria et al.33 Self-report on the MDS-UPDRS. Mattis
DRS, Neuropsychological assessment.
Cross-sectional study. Small sub-group
sizes. Well characterised groups.
Assessed ON medication (if motor
fluctuations present).
Mack et al.43 Self-reports on a study specific
questionnaire
Cross-sectional study. No comparator
group. Large, well characterised
population; MMSE reported. Medication
status at time of assessment not stated.
Mathias39 Discrepancy scores: subject vs informant on
the NBAP, DEX & NRS-Revised
Case-control study. Control group matched
for age, education and IQ. Small group
sizes. PD group described as not having
dementia, but cognitive results not
reported. Medication status at time of
assessment not stated.
McKinlay et al.28 Discrepancy scores: subject vs informant on
the Frontal Systems Behaviour Scale
Cross-sectional study. No comparator
group. Well characterised but small
group: MMSE reported.
PD group assessed ON medication.
Mikos et al.40 Discrepancy scores: subject vs informant on
the Berkeley Expressivity Questionnaire
Case control study. Controls matched for
age, cognition & education but more
depressive symptoms in PD group. Small
group sizes. PD group assessed ON
medication.
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3.4 | Timing of assessments
Dopaminergic therapies may impact on cognitive44 and neuropsychiatric
symptoms,45 but most studies did not report whether participants were
assessed in the ON or OFF medication state (Tables 3 and 6). Of the
studies of awareness of cognitive symptoms, 14 did not report the partici-
pants' medication state at the time of assessment, 6 assessed whilst ON
medication, and 1 whilst ON and OFF medication. Studies of awareness
of neuropsychiatric symptoms did not state medication timing in
13 instances, whilst 5 studies assessed participants ON medication.
4 | DISCUSSION
4.1 | Awareness of cognitive symptoms
Cognitive decline is often seen in people with PD, with older individ-
uals being most vulnerable.46 Studies of awareness of cognitive symp-
toms have variable results, with some showing intact
awareness,20,47-49 and others finding under or over-estimation of cog-
nitive functioning.19,24,50,51 The majority of studies have focused on
different aspects of memory.19-21,42,47-49,52-55 Only five studies were
found which focused on awareness of executive function,24,27,51,56,57
four used a global measure of cognition22,50,58,59 and one investigated
awareness of spoken language functioning.60
It is probable that awareness of memory functioning varies
across the disease course. Lehrner et al.52 examined a range of
groups across the spectrum of cognitive decline, including Subjective
Cognitive Decline (SCD), PD with non-amnestic MCI or amnestic
MCI, non-PD related non-amnestic or amnestic MCI and AD. A gra-
dient of worsening awareness for cognition performance was found,
with the SCD group under-estimating their performance, non-
amnestic MCI persons with or without PD having a level of aware-
ness indistinguishable from controls, whilst those with amnestic MCI
or AD showed reduced awareness, with the AD group being most
severely affected. Orfei et al.22 made similar findings, with significant
loss of awareness of cognition being seen in 36% of those with PDD
and 16% of those with multi-domain MCI-PD, whilst awareness was
retained by cognitively intact PD participants and those with single-
domain PD-MCI.
Awareness of cognitive functioning can be sub-divided into a
number of processes: real-time performance monitoring; registration
of positive and negative external feedback; comparison of current
with past ability; integration and updating of an internal model of
one's own abilities, and using this model to consciously report current
and predict future performance.61,62 How these individual aspects of
TABLE 6 (Continued)
Study Mesure of awareness Study quality summary
Noe et al.35 Informant reports Case control study: DLB, PDD and AD
groups. Small group sizes.
Neuropsychology results reported.
Medication status at time of assessment
not stated.
Papapetropoulos et al.29 University of Miami PD Hallucinations
Questionnaire
Questionnaire validation study. No
comparator group. Good group size, well
characterised. Medication status at time
of assessment not stated.
Serrano & Serrano30 Discrepancy scores: subject vs informant on
the Neuropsychiatric Inventory
Cross-sectional study. Good group size but
limited participant characterisation.
PD group assessed ON medication.
Schiehser et al.34 Discrepancy scores: subject vs informant on
prediagnosis & current ratings using
FrSBe. Neuropsychological evaluation &
carer ZBI.
Cross-sectional study. Good group size &
participant characterisation. Medication
status during assessment not stated.
Starkstein et al.31 Discrepancy scores: subject vs informant on
the Anosognosia questionnaire-dementia
Case control study (PDD and AD groups).
Neuropsychology results reported.
PD group assessed ON medication.
Valentino et al.32 Discrepancy scores: Apathy Evaluation
Scale carer and participant reports.
Neuropsychological evaluation
Cross-sectional study. Moderate group
sizes. Those with “overt cognitive
impairment” excluded, but mean MMSE
22.83 (SD 4.71), indicating the presence
of participants with significant cognitive
impairment. Medication status of
participants during testing not stated.
Abbreviations: BDI-II, Beck Depression Inventory version 2; MMP, Mini-mental Parkinson's; NBAP, Neuropsychology Behavior and Affect Profile; NRS-R,
Neurobehavioural Functioning Scale- Revised version.
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metacognition are affected by PD and other forms of neu-
rodegeneration remains an area of considerable debate. Participants
in two studies were found to have intact global knowledge of their
memory ability, but to be inaccurate when estimating performance
after a task.53,55 This suggests impaired memory performance moni-
toring. A further study compared awareness of memory function on
time and event-based memory tasks.54 Both performance and self-
ratings on the event-based memory task were at control level. How-
ever, people with PD were inaccurate on the time-based memory task
and showed impaired pre-task performance predictions, although
post-task performance ratings were intact. This implies that aware-
ness of memory ability is task specific and linked to task performance.
Impaired self-monitoring was found in a study investigating self-
awareness of speech errors, and this correlated with naming ability.60
People with PD also make less use of “aide-memoire” strategies such
as diaries or environmental cues,48 which may reflect a lack of aware-
ness of memory difficulties.
Different aspects of cognitive awareness can be explored using
dedicated tasks, such as those probing feeling of knowing (FoK) - an
individual's judgement of how likely they are to recognise an item
they failed to spontaneously recall. The accuracy of FoK judgements
appears to be linked to general cognitive status in PD, with cognitively
intact individuals performing normally,47 in contrast to those with mild
cognitive decline, who show significant deficits.21,53 The PD pheno-
type may also influence cognitive awareness. Yu et al.49 explored FoK
in tremor predominant PD vs those with an akinetic-rigid phenotype.
In the akinetic-rigid group FoK decisions were at chance level, but the
tremor predominant group were unimpaired. FoK correlated with
memory ability in the akinetic-rigid group, whereas executive function
was implicated in those with tremor predominant PD.
As with awareness of mnemonic ability, there is a spectrum of
insight into executive functioning. Both over-estimation and under-
estimation of executive functioning has been seen.24,43,51,57 Altered
symptom awareness is classically attributed to dysfunction in the
fronto-striatal circuits, implying that executive function and working
memory are involved. Kudlicka et al. found those with PD and executive
dysfunction to have impaired monitoring of their performance on an
executive function task.51 Baran et al. identified significant correlations
between executive functioning and accuracy of self-ratings of episodic
memory performance in healthy controls, but only modest links in those
with PD.21 This implies that executive function-dependent mechanisms
for self-monitoring may be dysfunctional in PD.
Imaging studies of healthy adults implicate the prefrontal cortex
(PFC) in awareness of cognitive ability. The medial PFC is postulated
to support prospective judgements of performance, whilst the lateral
PFC is involved in retrospective evaluations.63 The anterior cingulate
cortex and insula also appear to have a role in cognitive control. As
PD progresses the level of dopamine within the corticostriatal and
mesocortical loops is progressively reduced. With dopaminergic treat-
ments, the level is boosted, at times potentially to a supra-
physiological level. Both hypo- and hyperdopaminergic functioning
have been suggested as mechanisms for cognitive and metacognitive
dysfunction in PD.
Trenado et al. investigated memory awareness on a reversal
learning task in a small group of people with PD, both ON and OFF
dopaminergic medication.42 When OFF medication participants
showed reduced confidence in their correct responses, although per-
formance accuracy was unimpaired. Mattay et al. utilised fMRI to
investigate the impact of dopaminergic medication on working mem-
ory in people with PD.44 Activity was seen in the prefrontal cortex,
pericingulate cortex, anterior cingulate cortex and parietal cortex dur-
ing the task, with significantly more activation in the OFF state. How-
ever, task accuracy was also worse during the OFF state, suggesting
that dopaminergic stimulation improved efficiency within the
mesocortical dopaminergic system.
The role of dopamine in self-assessment of cognitive function in
healthy adults has been investigated using haloperidol, an antagonist
at the D2 autoreceptors which regulate dopamine release (and which
theoretically results in a subsequent increase in dopaminergic trans-
mission). During a recognition memory task, low dose haloperidol
improved memory accuracy in healthy adults but decreased confi-
dence.64 This was associated with more disorganised activity in the
frontostriatal networks, and a failure to modulate neural activity
according to the level of confidence in the decision. This mixture of
findings suggests that loss of cognitive awareness is not uniformly
affected across the PD spectrum, and that different aspects of aware-
ness may be differentially affected at different stages of the disease.
It may be that both low and high dopamine levels have an impact on
cognition and cognitive awareness, with suboptimal functioning in dif-
ferent dopaminergic circuits contributing to over and under-
confidence in cognition at different disease stages.
Factors such as low mood or adjustment reaction may also nega-
tively affect an individual's perception of their cognition. Castro
et al.50 investigated subjective cognitive symptoms in PD. Those self-
reporting cognitive difficulties performed normally on neuropsycho-
logical assessments but had higher levels of depressive symptomatol-
ogy. In contrast, the self-reported cognitively asymptomatic group
had impairments on objective cognitive tests. Sitek et al.55 also found
subjective cognitive decline to correlate with depressive symptoms.
These findings suggest that self-reported cognitive symptoms may
more accurately reflect lower mood than objective cognitive
functioning.
4.2 | Awareness of neuropsychiatric symptoms
Hallucinations, depression, apathy and sleep disturbances are all com-
mon features of PD, PDD and DLB. Hallucinations (typically visual)
are a core diagnostic feature of DLB and are common in PDD; they
were the most frequently studied type of neuropsychiatric symptom.
Other modalities of hallucinations can occur, and a major limitation of
the literature is a frequent failure to delineate the type of hallucina-
tion under study, or the grouping together of people experiencing hal-
lucinations or delusions. Of 12 studies including people with
hallucinations, 8 included hallucinations in any domain, 3 were specifi-
cally of visual hallucinations, and 1 feeling of presence.
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Studies of hallucinations were often not directly comparable due
to differences in study populations. Mack et al.43 interviewed 250 peo-
ple with PD and normal cognition, and found 26% to have hallucina-
tions or illusions, the majority with retained insight. Only 15.8% of
people reported hallucinations in a cohort of people with PD exam-
ined by Aarsland et al.1 Within the Aarsland et al. study cognitive sta-
tus clearly played a role, with the group as a whole having a mean
MMSE of 24.5, compared to 18.1 in the subgroup of people with hal-
lucinations and retained insight, and falling further to 13.5 of those
with psychosis.65 A longitudinal study of the clinical course of halluci-
nations found that the majority of people with PD lose insight over
time,41 although counterintuitively, an individual's baseline cognitive
status did not appear to predict the loss of awareness. The large
majority of those with feeling of presence hallucinations
(a phenomenon considered to be one of the earliest types of psy-
chotic symptoms in PD) retained insight.36 Altered awareness has
been association with greater depressive symptoms,36 global cognitive
dysfunction and higher severity of motor symptoms,33,41 although
several studies did not find an association between insight into hallu-
cinations and cognition.29,38
In those with DLB hallucinations are very common (unsurpris-
ingly, as their presence forms part of the DLB diagnostic criteria), with
estimates for the presence of psychosis varying from 31.3%35
to 63%.25
A link between dopaminergic medication load and hallucinations
without awareness has not emerged experimentally. Rather, the pres-
ence and severity of cognitive impairment and depression is positively
associated with psychotic symptoms. However there are a number of
issues which can potentially confound study results. Firstly, physicians
may reduce or avoid dopaminergic agents in response to the emer-
gence of psychotic symptoms; Goetz et al.41 reported an association
between retained awareness and a reduction in medication, and such
a pre-emptive medical approach may confound observational study
results. Secondly, ascertaining whether or not an individual has neuro-
psychiatric symptoms (with or without awareness) depends upon
reports from the subject and a knowledgeable informant. Caregiver
burden may artificially inflate report of neuropsychiatric symptoms
(due to caregiver distress heightening the impact of neuropsychiatric
symptoms, and hence greater reporting), whilst subjects may choose
to conceal unusual experiences or behaviours due to perceived social
stigma, or simply not recall them due to coexistent memory impair-
ment. On direct questionning, McKinlay et al.28 found patients to
report a greater number of hallucinatory experiences than caregivers.
Studies looking at a broader range of neuropsychiatric symptoms
have yielded conflicting results. Mathias et al. found good agreement
between patient and informant ratings on a number of symptom
scales, with the exception of depression, which informants rated as
being more severe than the participant themselves did.39 However
other studies have shown significant discrepancies between partici-
pant and informant ratings for a range of neuropsychiatric symp-
toms.28,30,32,34 Self-ratings of apathy were higher than informant
ratings in two studies,32,34 suggesting that external observers may not
be able to fully report changes to internal motivations. Valentino
et al.32 found self-rated apathy severity to correlate with reductions
in global cognition, executive functioning and motor ability, whilst
Schiehser et al.34 found higher levels of levodopa use to predict
greater discrepancies between self and informant apathy ratings.
Greater levels of carer burden and carer depression associated with
greater discrepancies on apathy and disinhibition ratings.34 Whether
this means that higher carer burden causes over-rating of symptoms
by carers, or that loss of symptom awareness by patients results in
greater carer burden (or both) is unclear.
A study of emotional expressivity (the ability to demonstrate feel-
ings, for example, by facial expression) revealed reduced expressivity
in those with PD, but with no evidence of loss of awareness of this at
the group level.40 In those individuals who did under-report symp-
toms, this was found to be associated with a higher level of apathy.
This suggests that loss of awareness for some psychiatric phenomena
may be inter-linked with wider cognitive functioning. Loss of aware-
ness for neuropsychiatric symptoms appears to be less severe in DLB
and PDD when compared to AD.25,31 However there is a paucity of
studies of awareness of neuropsychiatric symptoms other than hallu-
cinations in PD, and the DLB literature is extremely small.
4.3 | Methodological challenges
There are potential methodological issues with the study of cognitive
and neuropsychiatric symptom awareness. The commonest measure
of awareness used is a discrepancy score, where symptoms are rated
by the subject and an informant and the difference between the two
taken as a measure of the subject's awareness. This assumes the infor-
mant to have perfect insight into the subject's symptoms. Potential
confounders include informant bias, either positively by a desire to
protect the subject, or negatively by the stress of being a carer. In
addition, a subject may experience subtle changes which are not evi-
dent to an informant. We found there to be considerable heterogene-
ity in the cognitive assessment tools used. Not all studies reported the
global cognitive status of their participants, and those that did pre-
dominantly used a brief screening tool (typically the MMSE). Whilst
valuable, the MMSE and similar tools are insufficient to identify subtle
cognitive changes, PD-MCI, or domain specific impairments. The
Movement Disorders Society has developed detailed testing recom-
mendations for the diagnosis of MCI due to PD, and future studies
would benefit from using these more robust criteria.4,66 Interpreting
study findings becomes very challenging when a mixed population of
cognitive normal, mildly impaired people and those with dementia are
included. This issue also works to obscure the influence of cognitive
dysfunction on symptom awareness. A number of studies found links
between lower global cognitive scores and poorer awareness of cog-
nitive or neuropsychiatric symptoms, and it is widely accepted that
insight into psychotic symptoms tends to worsen in tandem with cog-
nitive decline. Frontal and temporal cortex is heavily implicated in loss
of symptom awareness in other neurodegenerative and psychiatric
disorders,13,67 and in loss of awareness of cognitive symptoms in
PD. However there is little known about how functioning in specific
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cognitive domains influences and interacts with neuropsychiatric
symptom awareness. Our understanding of how symptom awareness
evolves over time in PD and DLB would be greatly enhanced by work
utilising detailed, domain specific neuropsychological assessment, and
advanced techniques such as functional neuroimaging.
5 | CONCLUSIONS
The findings from the literature investigating awareness of cognitive
and neuropsychiatric symptoms in people with PD are mixed and lim-
ited by methodological heterogeneity, but altered symptom aware-
ness is clearly a common phenomenon. A far smaller body of research
into awareness in PD exists than in AD. We did not identify any stud-
ies of cognitive symptom awareness in people with DLB, and only
two investigating neuropsychiatric symptom awareness. Minimal
information is available regarding the influence of dopaminergic medi-
cations on neuropsychiatric symptom awareness.
Altered awareness in neurodegenerative conditions can greatly
exacerbate the impact of the primary condition itself. Those affected
may not seek appropriate help and support or refuse essential care.
Understanding how symptom awareness changes in PD and DLB, and
the impact this has on those affected and their significant others and
caregivers is a vital step in the pathway towards developing effective
management and therapeutic techniques. Given the chronic nature of
these conditions and the high incidence of progressive cognitive
decline, future longitudinal studies are needed to accurately establish
the neural underpinnings of symptom awareness, the most effective
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